U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Cover of Biomarker Tests for Molecularly Targeted Therapies

Biomarker Tests for Molecularly Targeted Therapies

Key to Unlocking Precision Medicine

Editors: Laurene A. Graig, Jonathan K. Phillips, and Harold L. Moses. Authors: ; ; ; .

Washington (DC): National Academies Press (US); .
ISBN-13: 978-0-309-38134-5ISBN-10: 0-309-38134-7

Every patient is unique, and the evolving field of precision medicine aims to ensure the delivery of the right treatment to the right patient at the right time. In an era of rapid advances in biomedicine and enhanced understanding of the genetic basis of disease, health care providers increasingly have access to advanced technologies that may identify molecular variations specific to an individual patient, which subsequently can be targeted for treatment. Known as biomarker tests for molecularly targeted therapies, these complex tests have the potential to enable the selection of the most beneficial treatment (and also to identify treatments that may be harmful or ineffective) for the molecular underpinnings of an individual patient's disease. Such tests are key to unlocking the promise of precision medicine.

Biomarker tests for molecularly targeted therapies represent a crucial area of focus for developing methods that could later be applicable to other areas of precision medicine. The appropriate regulatory oversight of these tests is required to ensure that they are accurate, reliable, properly validated, and appropriately implemented in clinical practice. Moreover, common evidentiary standards for assessing the beneficial impact of biomarker-guided therapy selection on patient outcomes, as well as the effective collection and sharing of information related to those outcomes, are urgently needed to better inform clinical decision making.

Biomarker Tests of Molecularly Targeted Therapies examines opportunities for and challenges to the use of biomarker tests to select optimal therapy and offers recommendations to accelerate progress in this field. This report explores regulatory issues, reimbursement issues, and clinical practice issues related to the clinical development and use of biomarker tests for targeting therapies to patients. Properly validated, appropriately implemented biomarker tests hold the potential to enhance patient care and improve outcomes, and therefore addressing the challenges facing such tests is critical.

Contents

This study was supported by Contracts 200-2011-38807,TO#27 (Centers for Disease Control and Prevention), 185616 (Janssen Diagnostics), HHSN2632012000741 (National Cancer Institute), NGC19399 (Novartis), and OPP-3028.0 (Susan G. Komen). The study was also supported by the American Society for Radiation Oncology, American Society of Clinical Oncology, Breast Cancer Research Foundation, College of American Pathologists, Gilead Sciences, Inc., Pfizer Inc., and Quest Diagnostics. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project.

Suggested citation:

National Academies of Sciences, Engineering, and Medicine. 2016. Biomarker tests for molecularly targeted therapies: Key to unlocking precision medicine. Washington, DC: The National Academies Press. doi: 10.17226/21860.

Copyright 2016 by the National Academy of Sciences. All rights reserved.
Bookshelf ID: NBK349100PMID: 26962610DOI: 10.17226/21860

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (6.7M)

Related information

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...